Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $43.46.
Several equities analysts recently commented on the stock. Guggenheim upped their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Leerink Partners raised their price objective on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Wolfe Research set a $35.00 target price on Tango Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 8th. Weiss Ratings raised Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group upgraded Tango Therapeutics from a “hold” rating to a “buy” rating and increased their price target for the stock from $27.00 to $60.00 in a report on Thursday, June 25th.
Check Out Our Latest Analysis on Tango Therapeutics
Tango Therapeutics Stock Performance
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, equities analysts predict that Tango Therapeutics will post -1.41 EPS for the current year.
Insider Buying and Selling at Tango Therapeutics
In other Tango Therapeutics news, insider Jessica Newcomb sold 8,200 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total value of $198,604.00. Following the sale, the insider owned 59,121 shares in the company, valued at $1,431,910.62. This trade represents a 12.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Adam Crystal sold 27,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the sale, the insider owned 115,743 shares in the company, valued at approximately $3,424,835.37. The trade was a 18.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 6.50% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in TNGX. Nykredit A S bought a new stake in Tango Therapeutics during the 2nd quarter valued at about $26,000. Allworth Financial LP bought a new position in Tango Therapeutics in the 2nd quarter worth about $35,000. Global Retirement Partners LLC bought a new position in Tango Therapeutics in the 2nd quarter worth about $122,000. State of Wyoming purchased a new position in shares of Tango Therapeutics during the first quarter worth approximately $128,000. Finally, AXQ Capital LP raised its stake in shares of Tango Therapeutics by 50.5% during the fourth quarter. AXQ Capital LP now owns 20,268 shares of the company’s stock valued at $180,000 after acquiring an additional 6,800 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.
About Tango Therapeutics
Tango Therapeutics, Inc is a biotechnology company focused on discovering and developing medicines that target cancer vulnerabilities. The company uses genetic screening, functional genomics and drug-discovery technologies to identify cancer-specific dependencies that may be addressed with targeted therapies.
Tango’s research activities center on precision oncology and immuno-oncology, including programs designed to selectively eliminate tumor cells or improve the ability of the immune system to recognize and attack cancer.
Featured Stories
- Five stocks we like better than Tango Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
